FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Coronary Drug-Eluting Stent
PMA: P160043
·
Supplement: S021
·
Decision Mar 8, 2019
Classifications
1
FEI Numbers
32
Registration Numbers
32
Basic Information
- Device Name
- Coronary Drug-Eluting Stent
- Trade Name
- Resolute Onyx Zotarolimus-Eluting Coronary Stent System
- PMA Number
- P160043
- Supplement Number
- S021
- Device Class
- FDA Class 3
- Product Code
- NIQ
- Generic Name
- Coronary drug-eluting stent
- Medical Specialty
- Unknown
- Advisory Committee
- Cardiovascular
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- March 8, 2019
- Date Received
- January 9, 2019
- Supplement Type
- Normal 180 Day Track No User Fee
- Supplement Reason
- Postapproval Study Protocol
- Expedited Review
- N
Advisory Committee Statement
Approval of the protocol for the post-approval study (PAS) protocol.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| NIQ | Coronary Drug-Eluting Stent | FDA class 3 | Unknown |